Cabergoline and quinagolide therapy for prolactinomas

Clinical Endocrinology

Volumn 53, Issue 5, 2000, Pages 549-550

  Webster, J ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; QUINAGOLIDE;

DRUG EFFICACY; HUMAN; NOTE; PRIORITY JOURNAL; PROLACTIN RELEASE; PROLACTINOMA; TREATMENT OUTCOME;

AMINOQUINOLINES; CROSS-OVER STUDIES; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; PITUITARY NEOPLASMS; PROLACTINOMA; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0033739739     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2000.01147.x     Document Type: Note

References (9)

1. Dopamine agonists and pituitary tumor shrinkage
2. Long-term treatment with cabergoline, a new long-lasting ergoline derivative, in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy
3. The effect of quinagolide and cabergoline, two selective dopamine receptor type-2 agonists, in the treatment of prolactinomas
4. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients
5. CV205-V502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia
6. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia
7. Use of cabergoline in the long term treatment of hyperprolactinemic and acromegalic patients
8. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinaemia: A double blind study
9. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhoea